英加妥珠单抗
化合物
英加妥珠单抗（INN：imgatuzumab），或译伊马曲单抗，是一种人源化单克隆抗体，设计用于治疗癌症。它是一种抗表皮生长因子受体抗体,[1]可作为免疫调节剂。[2][3]
| 单克隆抗体 | |
|---|---|
| 种类 | 完整抗体 |
| 目标 | EGFR |
| 临床资料 | |
| ATC码 |
|
| 识别信息 | |
| CAS号 | 959963-46-3 |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化学信息 | |
| 化学式 | C6434H9942N1718O2016S44 |
| 摩尔质量 | 145,028.96 g·mol−1 |
参考资料
编辑- ^ Kol A, Terwisscha van Scheltinga A, Pool M, Gerdes C, de Vries E, de Jong S. ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells. Oncotarget. July 2017, 8 (28): 45432–45446. PMC 5542198
. PMID 28467975. doi:10.18632/oncotarget.17139.
- ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 (PDF). WHO Drug Information. 2012, 26 (2) [2024-03-13]. （原始内容存档 (PDF)于2016-03-04）.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Imgatuzumab （页面存档备份，存于互联网档案馆）, American Medical Association.
